Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2019 1
2020 2
2022 1
2023 1
2024 1
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
c-MAF, a Swiss Army Knife for Tolerance in Lymphocytes.
Imbratta C, Hussein H, Andris F, Verdeil G. Imbratta C, et al. Front Immunol. 2020 Feb 14;11:206. doi: 10.3389/fimmu.2020.00206. eCollection 2020. Front Immunol. 2020. PMID: 32117317 Free PMC article. Review.
BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection.
Schmidt AC, Fairlie L, Hellström E, Luabeya Kany Kany A, Middelkoop K, Naidoo K, Nair G, Gela A, Nemes E, Scriba TJ, Cinar A, Frahm N, Mogg R, Kaufman D, Dunne MW, Hatherill M; BCG REVAX Study Team. Schmidt AC, et al. N Engl J Med. 2025 May 8;392(18):1789-1800. doi: 10.1056/NEJMoa2412381. N Engl J Med. 2025. PMID: 40334156 Free PMC article. Clinical Trial.
Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b-2a, double-blind, dose-escalation, randomised controlled trial.
Luabeya AKK, Rozot V, Imbratta C, Ratangee F, Shenje J, Tameris M, Mendelsohn SC, Geldenhuys H, Fisher M, Musvosvi M, Young C, Mulenga H, Bilek N, Mabwe S, Jelsbak IM, Rodríguez E, Puentes E, Doce J, Aguilo N, Martin C, Pillay C, Tait D, Russell M, Van Der Merve A, Rutkowski K, Hunt D, Ginsberg A, Scriba TJ, Hatherill M; A050 team. Luabeya AKK, et al. Among authors: imbratta c. Lancet Glob Health. 2025 Jun;13(6):e1030-e1042. doi: 10.1016/S2214-109X(25)00046-4. Epub 2025 Apr 15. Lancet Glob Health. 2025. PMID: 40250461 Free article. Clinical Trial.
Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic setting.
Tameris M, Rozot V, Imbratta C, Geldenhuys H, Mendelsohn SC, Kany Luabeya AK, Shenje J, Tredoux N, Fisher M, Mulenga H, Bilek N, Young C, Veldsman A, Botes N, Thole J, Fritzell B, Mukherjee R, Jelsbak IM, Rodriguez E, Puentes E, Doce J, Marinova D, Gonzalo-Asensio J, Aguilo N, Martin C, Scriba TJ, Hatherill M; MTBVAC 202 study team. Tameris M, et al. Among authors: imbratta c. EBioMedicine. 2025 Apr;114:105628. doi: 10.1016/j.ebiom.2025.105628. Epub 2025 Mar 17. EBioMedicine. 2025. PMID: 40101388 Free PMC article. Clinical Trial.